Empirica Therapeutics part of OBIO 2019 Capital Access Advisory Program

Today the Ontario Bioscience Innovation Organization (OBIO) announced its 2019 Capital Access Advisory Program (CAAP). Included in this year’s program is Empirica Therapeutics, which was launched by CCAB earlier this year. 

CAAP is designed to support “high-potential” Ontario companies to drive fundraising and lead to business and job growth. Read the detailed announcement. 

Leave a Reply

  • (will not be published)